New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

Today's Free Fly Stories
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | all day >>
08:39 EDTHFHFF Inc. initiated with an Overweight at Morgan Stanley
Subscribe for More Information
08:39 EDTSIEGY, ABB, GESiemens sees catching up with rivals on sales growth in 2018, Reuters reports
Subscribe for More Information
08:38 EDTCKSWClickSoftware appoints Joel Jeselsohn to CFO effective November 1
ClickSoftware announced that Joel Jeselsohn has been appointed Chief Financial Officer of the Company, effective November 1. He will be succeeding Shmuel Arvatz, who is departing the Company. Jeselsohn was previously the Company's Vice President Finance and Operations of the Americas.
08:38 EDTACTActavis signs option to acquire Rhythm Health
Subscribe for More Information
08:38 EDTCARAvis Budget price target lowreed to $56 from $62 at Barclays
Subscribe for More Information
08:37 EDTWCNWaste Connections expects FY14 results at 'upper end' of guidance range
The company said that it expects its FY14 earnings results to be at the upper end of its guidance range announced on July 22. On July 22, the company said that it expected its FY14 revenue to be in the range of $2.045B-$2.055B and adjusted EBITDA to be 34.5% of revenue. Guidance made during the company's Q3 earnings conference call
08:36 EDTSEICSEI Investments reports Q3 EPS 49c, consensus 47c
Subscribe for More Information
08:36 EDTBBYBest Buy reiterated as a top pick ahead of holiday season at Barclays
Subscribe for More Information
08:36 EDTCNOCNO Financial attractive following pullback, says FBR Capital
Subscribe for More Information
08:35 EDTFutures remain quiet following CPI data
Subscribe for More Information
08:34 EDTORMPOramed's oral insulin capsules show positive Phase IIa results
Oramed Pharmaceuticals reported positive top-line clinical results from its Phase IIa clinical trial of ORMD-0801, the company's proprietary oral insulin capsules, to treat type 1 diabetes. The trial was conducted in the U.S. under an FDA Investigational New Drug protocol. The prospective, randomized, double-blind, placebo controlled study evaluated the safety and impact of ORMD-0801 given before meals on the exogenous insulin requirements in 25 established type 1 diabetic patients. ORMD-0801 oral insulin given before meals appeared to be safe and well-tolerated. Although the study was not powered to show statistical significance, there were internally consistent trends observed. The data showed a decrease in rapid acting insulin, a decrease in post-prandial glucose, a decrease in daytime glucose by continual glucose monitoring and an increase in post-prandial hypoglycemia in the active group.
08:34 EDTGLPGlobal Partners increases quarterly cash distribution by 2.35% to 65.25c
Subscribe for More Information
08:33 EDTTLLP, QEPTesoro Logistics should be bought on weakness, says Oppenheimer
Subscribe for More Information
08:33 EDTIRMIron Mountain signs multi-year data center colocation agreement with Englewood
Iron Mountain announced it has signed a multi-year data center colocation agreement with Englewood Hospital and Medical Center, an acute care teaching hospital affiliated with the Mount Sinai School of Medicine in Englewood, New Jersey. Englewood Hospital will lease data center space within Iron Mountain’s underground data center located near Pittsburgh, Pennsylvania.
08:32 EDTPRGSProgress Software announcse intent to acquire Telerik for $262.5M
Subscribe for More Information
08:32 EDTBKS, SSNLFSamsung, Barnes & Noble introduce new large screen Galaxy Tab 4 NOOK
Subscribe for More Information
08:31 EDTTPIVTapImmune provides update on PolyStart vaccine platform
TapImmune provides an update on the status of its PolyStart vaccine technology platform in light of recent global concerns regarding pandemic infections and emerging viral threats such as Ebola and Enterovirus. While the current focus of the company’s PolyStart technology is on TapImmune’s cancer program, the company none-the-less strongly reaffirms that this core technology has widespread applicability in the development of vaccines for viral disease. The use of the company’s PolyStart technology increases the production of proprietary antigenic peptides of the vaccine by as much as FOUR-fold, thereby increasing vaccine potency, and potentially making manufacturing and commercialization of large volume vaccines more cost effective. While additional preclinical development is in progress, we fundamentally believe that our technology will have a significant impact in the development of vaccines for both cancer and emerging viral-disease.
08:31 EDTFNBF.N.B. Corp. reports Q3 adjusted EPS 21c, consensus 21c
Subscribe for More Information
08:31 EDTGTGoodyear Tire to begintesting US trucking fleets
Subscribe for More Information
08:30 EDTOSISOSI Systems, DHS enter into addendum to administrative agreement
OSI Systems announced that its Security division, Rapiscan Systems, and the Department of Homeland Security have entered into an Addendum to the Administrative Agreement signed in June 2013. Among other compliance measures, the Addendum extends the duration of the Administrative Agreement. OSI Systems CEO, Deepak Chopra, commented, “We are pleased to have reached this agreement with DHS. U.S. federal government agencies are counted among our closest and longest standing customer relationships and we look forward to continuing to provide these customers with state of the art technologies and services in years to come.”
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | all day >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use